ArticleVaccine2010
Forecasting the economic value of an Enterovirus 71 (EV71) vaccine.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 47 citations in OpenAlex.
- Disease burden of enterovirus 71 in rural central China: A community-based survey.Human vaccines & immunotherapeutics · 2015Trial
- Trial
- Molecular Evolutionary Dynamics of Coxsackievirus A6 Causing Hand, Foot, and Mouth Disease From 2021 to 2023 in China: Genomic Epidemiology Study.JMIR public health and surveillance · 2024Article
- Chinese parents' intention to vaccinate their 0-5-year-old children with the EV-71 vaccine against hand, foot, and mouth disease and willingness-to-pay.Frontiers in public health · 2024Article
- Article
- The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China.Emerging microbes & infections · 2021Article
- A method for hand-foot-mouth disease prediction using GeoDetector and LSTM model in Guangxi, China.Scientific reports · 2019Article
- Using Baidu index to nowcast hand-foot-mouth disease in China: a meta learning approach.BMC infectious diseases · 2018Article
- Cost-effectiveness of a national enterovirus 71 vaccination program in China.PLoS neglected tropical diseases · 2017Article
- Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.Human vaccines & immunotherapeutics · 2017Article
- A systems approach to vaccine decision making.Vaccine · 2017Article
- Cost effectiveness of medical devices to diagnose pre-eclampsia in low-resource settings.Development engineering · 2017Article
- N-terminal pro-brain natriuretic peptide levels associated with severe hand, foot and mouth disease.BMC infectious diseases · 2016Article
- Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy.Medical microbiology and immunology · 2016Review
- A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions.Human vaccines & immunotherapeutics · 2016Article
- EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.Emerging microbes & infections · 2016Review
- Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis.PLoS medicine · 2016Article
- Hand, Foot, and Mouth Disease in China: Modeling Epidemic Dynamics of Enterovirus Serotypes and Implications for Vaccination.PLoS medicine · 2016Article
- Article
- Is a multivalent hand, foot, and mouth disease vaccine feasible?Human vaccines & immunotherapeutics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Enterovirus 71 (EV71) is a growing public health concern, especially in Asia. A surge of EV71 cases in 2008 prompted authorities in China to go on national alert. While there is currently no treatment for EV71 infections, vaccines are under development. We developed a computer simulation model to determine the potential economic value of an EV71 vaccine for children (<5 years old) in China. Our results suggest that routine vaccination in China (EV71 infection incidence ≈0.04%) may be cost-effective when vaccine cost is $25 and efficacy ≥70% or cost is $10 and efficacy ≥50%. For populations with higher infection risk (≥0.4%), a $50 or $75 vaccine would be highly cost-effective even when vaccine efficacy is as low as 50%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.